UNSPSC 51151517: Cevimeline

This classification denotes a cholinergic agonist with the molecular formula C10H17NOS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9V0CDQ56E, chemically known as 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine but generally known as cevimeline, which bears US NIH Compound Identifier 83898. European Medicines Agency schedules Cevimeline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07461MIG. The term CEVIMELINE is an International Non-Proprietary Name.

UNSPSC 51151517 Cevimeline, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally designates a specific pharmaceutical compound (cevimeline, a muscarinic agonist used to treat dry mouth), but the two recent opportunities tagged with this code do not reflect pharmaceutical procurement aligned with the code's intended scope. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and drug deactivation systems—emergency response and harm-reduction products unrelated to cevimeline—with quarterly deliveries required and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, seeking vendor information on direct-to-manufacturer prescription programs and pharmacy benefit management strategies, which addresses pharmaceutical distribution infrastructure rather than procurement of a specific drug product. Neither opportunity reflects actual demand for cevimeline itself.

The mismatch between the code's pharmaceutical specificity and the actual work being solicited suggests either systematic tagging errors in the state and local opportunity database or that cevimeline sees negligible direct procurement activity through state and local channels at present. The issuing bodies—a county health department and a state HHS commission—represent the kinds of organizations that would purchase pharmaceutical products, but their recent solicitations target broader categories (emergency-response drugs, pharmacy benefit management frameworks) rather than cevimeline procurement. No representative opportunities for cevimeline supply, group purchasing agreements, or formulary inclusion emerged from recent postings. Firms pursuing this code should verify whether state and local Medicaid, workers' compensation, or health plan formularies actually list cevimeline as a covered therapeutic, or whether procurement activity in this space operates through existing group purchasing organizations or manufacturer direct relationships rather than open competitive solicitation.